Literature DB >> 22562532

Correlation of epigenetic aberrance with STAT3 signaling pathway in gastric carcinogenesis.

Fuli Gao1, Ying Lv, Yinxin Zhu, Min Chen, Shanshan Shen, Jun Cao, Xiaoping Zou.   

Abstract

BACKGROUND: It has been suggested that STAT3 signaling plays important roles in regulating epigenetic aberrance during tumorigenesis, especially in the expression of certain key epigenetic enzymes such as DNMTs, HDACs, and HMTs. However, there has been no report on the relationship of STAT3 signaling and epigenetic aberrance in gastrocarcinogenesis. AIM: The purpose of this study was to explore the interrelationship of STAT3 signaling pathway and epigenetic aberrance in gastrocarcinogenesis.
METHODS: Immunohistochemistry was utilized to examine the protein expressions of pSTAT3, DNMT1, HDAC1, and EZH2 in 153 tissue specimens, including 20 of normal gastric epithelium tissue, 21 of intestinal metaplasia (IM), 24 of dysplasia (DYS), 23 of early gastric cancer (EGC) and 65 of advanced gastric cancer (AGC), and then analyze their possible relationship with clinicopathological factors.
RESULTS: We found that the four protein expressions were obviously enhanced following the malignant process of gastric carcinogenesis. Pearson correlation analysis of all the pathological groups showed that expression of pSTAT3 was highly associated with DNMT1, but not with HADC1 and EZH2. However, significant correlations were detected among the expression of DNMT1, HDAC1, and EZH2. Further analysis of each pathological group demonstrated that pSTAT3's expression was dramatically related with DNTM1 in the IM (P = 0.021) and EGC groups (P = 0.013) and correlated with EZH2 in the DYS group (P = 0.020). Furthermore, pSTAT3's expression was associated with T staging (P = 0.015) in the AGC group, whereas DNMT1 was associated with gender (P = 0.021), HDAC1 with Lauren classification (P = 0.007), and EZH2 with T staging (P = 0.003) and lymphatic staging (P = 0.038).
CONCLUSIONS: The STAT3 signaling pathway may correlate with epigenetic aberrance during gastrocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22562532     DOI: 10.1007/s10620-012-2152-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  23 in total

1.  Gastric cancer incidence rate to rise.

Authors: 
Journal:  Manag Care       Date:  2010-10

2.  Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer.

Authors:  Yasuko Matsukawa; Shuho Semba; Hirotaka Kato; Akihiko Ito; Kazuyoshi Yanagihara; Hiroshi Yokozaki
Journal:  Cancer Sci       Date:  2006-06       Impact factor: 6.716

Review 3.  Epstein-Barr virus and gastric carcinoma.

Authors:  Masashi Fukayama
Journal:  Pathol Int       Date:  2010-05       Impact factor: 2.534

4.  STAT3 induces transcription of the DNA methyltransferase 1 gene (DNMT1) in malignant T lymphocytes.

Authors:  Qian Zhang; Hong Y Wang; Anders Woetmann; Puthiyaveettil N Raghunath; Niels Odum; Mariusz A Wasik
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

5.  Enhancer of zeste homolog 2 expression is associated with tumor cell proliferation and metastasis in gastric cancer.

Authors:  Jung Hye Choi; Young Soo Song; Jin Sun Yoon; Kang Won Song; Young Yiul Lee
Journal:  APMIS       Date:  2010-03       Impact factor: 3.205

6.  Autoregulation of mouse histone deacetylase 1 expression.

Authors:  Bernd Schuettengruber; Elisabeth Simboeck; Harald Khier; Christian Seiser
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

7.  Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.

Authors:  Xiao-Ping Zou; Bin Zhang; Xiao-Qi Zhang; Min Chen; Jun Cao; Wen-Jia Liu
Journal:  Hum Pathol       Date:  2009-08-19       Impact factor: 3.466

Review 8.  Epigenetics in cancer.

Authors:  Shikhar Sharma; Theresa K Kelly; Peter A Jones
Journal:  Carcinogenesis       Date:  2009-09-13       Impact factor: 4.944

Review 9.  Helicobacter pylori and gastric carcinogenesis.

Authors:  P Correa
Journal:  Am J Surg Pathol       Date:  1995       Impact factor: 6.394

10.  The histone demethylase RBP2 Is overexpressed in gastric cancer and its inhibition triggers senescence of cancer cells.

Authors:  Jiping Zeng; Zheng Ge; Lixiang Wang; Qiao Li; Na Wang; Magnus Björkholm; Jihui Jia; Dawei Xu
Journal:  Gastroenterology       Date:  2009-10-20       Impact factor: 22.682

View more
  6 in total

1.  Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer.

Authors:  Yong Liu; Jingyu Deng; Xuegang Luo; Yuan Pan; Li Zhang; Rupeng Zhang; Han Liang
Journal:  Med Oncol       Date:  2014-12-04       Impact factor: 3.064

2.  Role of EZH2 protein expression in gastric carcinogenesis among Asians: a meta-analysis.

Authors:  Lin Guo; Teng-Fei Yang; Shi-Chao Liang; Ji-Xiang Guo; Qiang Wang
Journal:  Tumour Biol       Date:  2014-04-05

3.  β1,6 GlcNAc branches-modified PTPRT attenuates its activity and promotes cell migration by STAT3 pathway.

Authors:  Jingjing Qi; Na Li; Kun Fan; Peng Yin; Chao Zhao; Zengxia Li; Yi Lin; Liying Wang; Xiliang Zha
Journal:  PLoS One       Date:  2014-05-20       Impact factor: 3.240

4.  The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy.

Authors:  Lin-Lin Cao; Zhihong Yue; Lianhua Liu; Lin Pei; Yue Yin; Li Qin; Jie Zhao; Huixin Liu; Hui Wang; Mei Jia
Journal:  Oncotarget       Date:  2017-06-13

5.  SAMSN1 is highly expressed and associated with a poor survival in glioblastoma multiforme.

Authors:  Yong Yan; Lei Zhang; Tao Xu; Jinxu Zhou; Rong Qin; Chao Chen; Yongxiang Zou; Da Fu; Guohan Hu; Juxiang Chen; Yicheng Lu
Journal:  PLoS One       Date:  2013-11-22       Impact factor: 3.240

Review 6.  Prognostic Value and Clinicopathological Significance of p-stat3 Among Gastric Carcinoma Patients: A Systematic Review and Meta-Analysis.

Authors:  Kun Ji; Liyan Zhang; Mingxuan Zhang; Qi Chu; Xin Li; Wei Wang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.